Lineage Cell Therapeutics Receives U.S. Patent Covering AlloSCOPE 5D Cell Manufacturing Platform
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company focused on developing novel allogeneic, “off-the-shelf” cell therapies for serious medical conditions, has announced an important intellectual property milestone for its proprietary cell manufacturing technology. The United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,692,476, covering key aspects of Lineage’s AlloSCOPE cell manufacturing platform, including its proprietary AlloSCOPE “5D” technology.
The newly issued patent strengthens Lineage’s intellectual property position in the field of pluripotent stem cell manufacturing and supports the company’s broader efforts to develop scalable cell-based therapies. The patent is expected to remain in force until June 9, 2043, providing long-term protection for the covered manufacturing technologies.
AlloSCOPE, which stands for Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent cell Engineering, is designed to address some of the manufacturing challenges associated with producing pluripotent stem cell-derived therapies at commercial scale. Lineage’s AlloSCOPE 5D approach is particularly focused on producing high volumes of low-passage, undifferentiated and genetically stable pluripotent stem cells that can respond synchronously to differentiation signals.
According to the company, this manufacturing strategy is intended to provide greater control over the differentiation process compared with conventional two-dimensional (2D) and three-dimensional (3D) manufacturing approaches. The technology could potentially support the large-scale production of cell therapies intended for indications that require high doses, including Type 1 Diabetes.
Patent Protects AlloSCOPE Manufacturing Technology
The issuance of U.S. Patent No. 12,692,476 represents a significant development for Lineage as it continues to build its proprietary technology platform around allogeneic cell therapies.
Unlike autologous cell therapies, which generally involve collecting and processing cells from individual patients, allogeneic therapies are designed to use cells produced in advance from a donor-derived source. This creates the possibility of manufacturing therapeutic cells in large quantities and storing them for use as “off-the-shelf” products.
However, achieving reliable large-scale manufacturing of pluripotent stem cell-derived products remains a major technical challenge. Cell expansion, consistency, differentiation control, genetic stability, aseptic processing and manufacturing scale can all influence the quality and commercial viability of a cell therapy.
Lineage’s AlloSCOPE platform is designed to address these challenges through a manufacturing approach that combines characteristics of conventional 2D and 3D systems.
Brian M. Culley, Chief Executive Officer of Lineage Cell Therapeutics, described the newly issued patent as an important company asset because it addresses what Lineage believes are two major barriers to the commercialization of pluripotent cell-derived therapies.
According to Culley, traditional pluripotent cell expansion systems generally rely on either 2D or 3D approaches, with each offering distinct benefits and limitations.
Combining the Benefits of 2D and 3D Manufacturing
In conventional 2D manufacturing, cells are expanded across a surface. This approach can provide a high degree of control and synchronization during cell production, but scaling the process can be difficult. The systems may also require substantial manipulation and handling as production volumes increase.
Three-dimensional manufacturing systems, meanwhile, can offer greater scalability and potentially reduce certain aseptic processing risks. However, according to Lineage, moving cells into a 3D environment can make it more difficult to maintain the synchronization and consistency that can be achieved in traditional 2D systems.
The AlloSCOPE 5D approach is designed to combine these advantages. The technology uses microcarriers as a 2D growth surface inside a 3D bioreactor. This configuration allows cells to grow on defined surfaces while being processed within a scalable bioreactor environment.
Lineage believes that this arrangement can potentially provide the control and reproducibility associated with 2D cell expansion while maintaining the scalability of a 3D manufacturing system.
The company also believes the approach could enable differentiation of cell-based product candidates directly within the manufacturing environment, reducing the amount of handling required between production stages.
This could have implications for manufacturing efficiency and product consistency. Minimizing manual manipulation may help reduce opportunities for contamination while also improving the ability to control production processes.
Potential for High-Dose Cell Therapy Applications
One of the most important potential applications for Lineage’s AlloSCOPE 5D platform is the manufacturing of therapies that require very large numbers of cells per patient.
Some cell therapy approaches may require relatively modest doses, while others could require hundreds of millions or even billions of cells for a single treatment. Manufacturing sufficient quantities of high-quality cells while maintaining consistency can become increasingly difficult as dose requirements rise.
Lineage believes its 5D technology could help address this challenge by enabling high-volume expansion of pluripotent stem cells while maintaining characteristics important for downstream therapeutic manufacturing.
The company specifically highlighted Type 1 Diabetes as an example of an indication where very high cell doses may ultimately be required. Cell replacement approaches for Type 1 Diabetes are being investigated as a potential way of restoring insulin-producing cell function. Such strategies may require substantial quantities of therapeutic cells to achieve the desired clinical effect.
A scalable manufacturing platform could therefore be an important component of making high-dose cell therapies commercially feasible.
Manufacturing From GMP Cell Banks
Lineage also highlighted its experience in producing multiple batches of a cell-based product candidate for clinical development. The company said these batches have been produced from a Good Manufacturing Practice (GMP) working cell bank that was itself derived from a GMP master cell bank (MCB).
The use of standardized master and working cell banks is an important component of scalable allogeneic cell therapy manufacturing. Rather than generating a unique cell product for every patient, an established cell bank can serve as a consistent starting material for multiple production batches.
Lineage believes that the manufacturing expansion capabilities it has already demonstrated could potentially enable production of millions of vials of “off-the-shelf” cell therapy material from a master cell bank.
Such a manufacturing model could offer significant advantages compared with individualized autologous cell therapy manufacturing. Autologous approaches typically require patient-specific collection, processing and manufacturing, which can introduce logistical complexity and potentially increase costs.
An allogeneic platform, by contrast, is intended to support centralized manufacturing of therapeutic cells that can subsequently be stored and distributed for use in multiple patients.
Lineage believes this model could result in production costs substantially below those associated with autologous therapies, although the ultimate cost and commercial viability of any product would depend on clinical, manufacturing and regulatory factors.
Supporting Commercial-Scale Production
The ability to manufacture large quantities of consistent cell products is widely viewed as one of the critical factors in the development of commercially viable cell therapies.
Clinical success alone does not guarantee that a cell therapy can become broadly available. Developers must also establish manufacturing processes capable of producing sufficient quantities of a consistent product under appropriate quality standards.
For therapies requiring high doses, the manufacturing challenge becomes even more significant. Production systems must be capable of expanding cells efficiently while maintaining their identity, potency and other critical characteristics.
Lineage believes its AlloSCOPE 5D technology may provide a pathway toward these goals by combining scalable bioreactor manufacturing with controlled cell expansion and differentiation.
The newly issued patent provides intellectual property protection around this technology, potentially strengthening Lineage’s competitive position as it develops its pipeline of allogeneic cell therapies.
Application to COR1 and Future ILT1 Development
Lineage has already deployed AlloSCOPE 5D methods in support of its corneal endothelial cell transplant program, known as COR1.
Corneal endothelial disorders can affect the ability of the cornea to maintain its normal clarity and function. Cell replacement therapies are being investigated as an approach to restore or improve corneal endothelial function without relying exclusively on traditional surgical strategies.
Lineage plans to continue using the AlloSCOPE 5D platform as it advances its development efforts toward ILT1.
The application of the technology to its corneal endothelial program provides the company with an opportunity to further develop and validate its manufacturing processes while supporting the production of cell-based therapeutic candidates.
The company’s broader strategy is based on the development of allogeneic, scalable cell therapies that can potentially be manufactured in advance and made available as standardized products.
Strengthening Lineage’s Intellectual Property Position
The patent issued by the USPTO adds another layer of protection to Lineage’s proprietary manufacturing capabilities. With an expected expiration date of June 9, 2043, the patent provides the company with long-term intellectual property coverage for the claimed aspects of its AlloSCOPE platform.
For biotechnology companies developing advanced cell therapies, intellectual property protection can play an important role in supporting long-term commercial strategies. Patents covering manufacturing technologies can be particularly valuable because manufacturing processes may determine whether a therapeutic candidate can be produced consistently and economically at scale.
Culley emphasized that Lineage’s experience with clinical manufacturing, combined with its AlloSCOPE 5D technology, could position the company to address the production requirements associated with high-dose cell therapies.
Lineage believes its manufacturing platform could potentially support products requiring doses of up to one billion cells per patient. Such capabilities may become increasingly important as researchers explore cell replacement approaches for diseases where substantial numbers of functional cells are needed.
The issuance of U.S. Patent No. 12,692,476 represents a notable milestone for Lineage Cell Therapeutics as it continues to advance its cell therapy programs and proprietary manufacturing platform.
Through AlloSCOPE 5D, the company is seeking to address several longstanding challenges in pluripotent stem cell manufacturing, including scalability, synchronization, consistency, genetic stability and reduced manufacturing manipulation.
By using microcarriers within a 3D bioreactor environment, Lineage aims to combine the controlled growth characteristics of 2D systems with the scalability associated with 3D manufacturing. The company believes this approach could facilitate the production of large quantities of standardized cell material while maintaining the quality and consistency required for clinical and potentially commercial applications.
The technology is already being used to support Lineage’s COR1 corneal endothelial cell transplant program, with plans to continue applying the platform as the company advances toward ILT1.
As the cell therapy industry moves toward broader clinical development and commercialization, scalable and cost-effective manufacturing will remain a central consideration. Lineage’s latest patent provides additional protection for its approach as the company works to develop “off-the-shelf” therapies capable of addressing serious medical conditions.
With intellectual property protection extending into 2043 and continued deployment of the platform across its development programs, Lineage is positioning AlloSCOPE 5D as an important component of its long-term strategy for producing next-generation allogeneic cell therapies at potentially commercial scale.
About the AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering) Platform
The AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering) platform highlights the key attributes of Lineage’s in-house technology and describes a differentiation and production modality from which Lineage can manufacture millions of doses of an allogeneic, cell-based product derived from a single initial pluripotent cell line, conferring consistent, cost-effective, and scalable cell-based production and which can be applied across multiple programs.
From our proprietary AlloSCOPE platform, we successfully completed a current Good Manufacturing Practice (“cGMP”) production run from a custom, two-tiered cell banking system, featuring a genetically-stable master cell bank (MCB) created from a single, well-characterized pluripotent cell line, which generated a working cell bank (WCB), which then provided the source material for two final cell-based product candidates. AlloSCOPE “5D” describes an application of AlloSCOPE with the goal of higher scale production with reduced manipulation.
Allogeneic cell therapy product manufacturing generally involves three basic steps: (i) expansion of pluripotent cells; (ii) differentiation of cells into the desired cell type, and (iii) further expanding those cells prior to harvesting, filling and cryopreserving the final product. In cell therapy manufacturing, how cells are grown and organized during differentiation and/or expansion can affect their scalability, phenotype, process control, manufacturing cost, and the characteristics of the final product.
In a 2D process, cells are typically grown as an adherent monolayer on a flat, coated surface, such as a culture flask or multilayer vessel. This method allows for close control of cell growth and morphology, but scaling generally requires increasing the number of culture vessels, which can add labor, facility space, cost, and process complexity. In a 3D process, cells are grown in a three-dimensional environment, often as aggregates or spheroids within a bioreactor.
This method can support automation, higher cell densities, and greater scale from a smaller footprint, but requires a tradeoff of less control and loss of synchronization. Lineage’s AlloSCOPE 5D technology is the Company’s innovative process of merging 2D manufacturing with 3D scale.
By creating 2D-like growth conditions within a controlled, scalable 3D environment, AlloSCOPE 5D is designed to address one of the central manufacturing challenges in large-scale cell therapy manufacturing, by harnessing the precision and uniformity advantages of 2D culture with the scalability, efficiency, and automation capabilities of 3D bioreactor systems, while simultaneously avoiding the scale limitations of 2D methods and unresolved challenges associated with aggregate-based 3D culture.
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious medical conditions. Lineage’s programs are based on its proprietary cell-based technology platform, AlloSCOPE™ (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and associated development and manufacturing capabilities.
From this proprietary AlloSCOPE platform, Lineage develops, manufactures, and tests specialized human cells with anatomical and physiological functions similar or substantially identical to cells found naturally in the human body. These cells are created by applying directed differentiation protocols to established, well-characterized, and self-renewing pluripotent cell lines. These protocols generate cells with characteristics associated with specific and desired developmental lineages, and in some instances may be designed to have additional beneficial properties.
Cells derived from such lineages are transplanted into patients in an effort to replace or support cells that are absent or dysfunctional due to degenerative disease, aging, or traumatic injury, and to restore or augment the patient’s functional activity. Lineage’s pipeline currently includes: (i) OpRegen® cell therapy, a retinal pigment epithelial cell therapy in Phase 2a development under a worldwide collaboration with Roche and Genentech, a member of the Roche Group, for the treatment of geographic atrophy secondary to age-related macular degeneration;
(ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of spinal cord injuries;
(iii) ReSonance® (ANP1), an auditory neuronal progenitor cell therapy in preclinical development under a collaboration with William Demant Invest A/S for the potential treatment of auditory neuropathy;
(iv) PNC1, a photoreceptor neural cell therapy research initiative being evaluated for development for the potential treatment of vision loss due to photoreceptor dysfunction or damage; (v) RND1, a novel hypoimmune induced pluripotent stem cell line being evaluated for development under a gene editing partnership;
(vi) ILT1, a cell therapy manufacturing initiative focused on the issue of large-scale production of undifferentiated pluripotent cells, which if successful and applied to an islet cell differentiation protocol, could be evaluated for the production of islet cells to support a potential treatment of Type 1 Diabetes; and (vii) COR1, a corneal endothelial disease cell therapy in preclinical development for the potential treatment of corneal endothelial disease.